Chimeric small molecules for the recruitment of antibodies to cancer cells

US9296708B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9296708-B2
Application numberUS-201414480204-A
CountryUS
Kind codeB2
Filing dateSep 8, 2014
Priority dateMay 13, 2008
Publication dateMar 29, 2016
Grant dateMar 29, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound according to the chemical structure: wherein A is an antibody binding moiety according to the chemical formula: Where Y′ is H or NO 2 ; X is O, CH 2 , NR 1 , S(O), S(O) 2 , —S(O) 2 O, —OS(O) 2 , or OS(O) 2 O; R 1 is H, a C 1 -C 3 alkyl group, or a —C(O)(C 1 -C 3 ) group; X′ is CH 2 , O, N—R 1 ′ or S; R 1′ is H or C 1 -C 3 alkyl; Z is a bond, a monosaccharide, disaccharide, oligosaccharide, glycoprotein or glycolipid; X b is a bond, O, CH 2 , NR 1 or S; X″ is O, CH 2 , NR 1 ; R 1 is H, a C 1 -C 3 alkyl group or a —C(O)(C 1 -C 3 ) group; n is 1 or 2; n 1 is 1; B is a cell binding moiety according to the chemical formula: Where X 1 and X 2 are each independently CH 2 , O, NH or S; X 3 is O, CH 2 , NR 1 , S(O), S(O) 2 , —S(O) 2 O, —OS(O) 2 , or OS(O) 2 O; R 1 is H, a C 1 -C 3 alkyl group, or a —C(O)(C 1 -C 3 ) group; k is an integer from 1 to 15; L is a linker according to the chemical formula: Or L is a polyethylene gycol, polypropylene glycol or polypropylene-co-polyethylene glycol linker having between 1 and 20 glycol units; Where R a is H, C 1 -C 3 alkyl or alkanol or forms a proline side chain with R 3 R 3 forms a proline side chain with R a or is a side chain derived from an amino acid selected from the group consisting of alanine, arginine, asparagine, aspartic acied, cysteine, glutamine, glutamic acid, glycine, histicine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan and valine; and m is an integer from 1 to 30; or L is a linker according to the chemical formula: Where Z and Z′ are each independently a bond, —(CH 2 ) i —O, —(CH 2 ) i —S, —(CH 2 ) i —N—R , wherein said —(CH 2 ) i group, if present in Z or Z′, is bonded to[CON] if present, antibody binding terminus (ABT) or cell binding terminus (CBT); Each R is independently H, or a C 1 -C 3 alkyl or alkanol group; Each R 2 is independently H or a C 1 -C 3 alkyl group; Each Y is independently a bond, O, S or N—R; Each i is independently 0 to 100; D is  or a bond, with the proviso that Z, Z′ and D are not each simultaneously bonds; j is 1 to 100; m′ is 1 to 100; n′ is 1 to 100; and X 1 is O, S or N—R, R is as defined above; and [CON] is a bond or a moiety according to the chemical structure: Where X 2 is O, S, NR 4 , S(O), S(O) 2 , —S(O) 2 O, —OS(O) 2 , or OS(O) 2 O; X 3 is NR 4 , O or S; and R 4 is H, a C 1 -C 3 alkyl or alkanol group, or a —C(O)(C 1 -C 3 ) group; or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1 wherein A is X is O or NH; Y′ is H; X′ is O; and Z is a bond, a monosaccharide or a disaccharide; and Where X b is a bond or O, or a pharmaceutically acceptable salt thereof. 3. The compound according to claim 1 wherein A is 4. The compound according to claim 1 wherein A is 5. The compound according to claim 4 wherein X′ is O or N—R 1 ′ and R 1 ′ is H. 6. The compound according to claim 4 wherein X′ is O. 7. The compound according to claim 2 wherein A is 8. The compound according to claim 4 wherein Z is a monosaccharide selected from the group consisting of aldoses, ketoses and aminosugars. 9. The compound according to claim 4 wherein Z is a monosaccharide selected from the group consisting of D-glyceraldehdye, D-erythrose, D-Threose, D-ribose, D-arabinose, D-xylose, D-lyxose, D-allose, D-altrose, D-Glucose, D-Mannose, D-gulose, D-idose, D-galactose, dihydroxyacetone, D-erythrulose, D-ribulose, D-xylulose, D-Psicose, D-Fructose, D-Sorbose, D-Tagatose, galactoseamine, sialic acid and N-acetylglucosamine. 10. The compound according to claim 4 wherein Z is a disaccharide selected from the group consisting of sucrose, which may be optionally N-acetylated, lactose, which may be optionally N-acetylated, maltose, which may be optionally N-acetylated, trehalose, which may be optionally N-acetylated, cellobiose, which may be optionally N-acetylated, kojibiose, which may be optionally N-acetylated, nigerose, which may be optionally N-acetylated, isomaltose, which may be optionally N-acetylated, β,β-trehalose, which may be optionally N-acetylated, sophorose, which may be optionally N-acetylated, laminaribiose, which may be optionally N-acetylated, gentiobiose, which may be optionally N-acetylated, turanose, which may be optionally N-acetylated, maltulose, which may be optionally N-acetylated, palatinose, which may be optionally N-acetylated, mannobiose, which may be optionally N-acetylated, melibiose, which may be optionally N-acetylated, melibiulose, which may be optionally N-acetylated, rutinose, which may be optionally N-acetylated, rutinulose, which may be optionally N-acetylated and xylobiose, which may be optionally N-acetylated. 11. The compound according to claim 1 wherein said linker is group according to the chemical formula: Where R a is H or forms a proline side chain with R 3 and R 3 forms a proline side chain with R a or is a side chain derived from an amino acid selected from the group consisting of alanine, arginine, asparagine, aspartic acied, cysteine, glutamine, glutamic acid, glycine, histicine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan and valine; and m is an integer from 1 to 10. 12. The compound according to claim 1 wherein [CON] is a  group, where X 2 is O, S or NR 4 ; and R 4 is H or a C 1 -C 3 alkyl or alkanol group. 13. The compound according to claim 1 wherein said linker is a group according to the formula: Wherein m is an integer from 1 to 10.

Assignees

Inventors

Classifications

  • Human Necessities · mapped topic

  • C07D249/04Primary

    1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles · CPC title

  • 1,2,3-Triazoles · CPC title

  • Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

  • C07K16/44Primary

    against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9296708B2 cover?
The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.
Who is the assignee on this patent?
Univ Yale
What technology area does this patent fall under?
Primary CPC classification C07D249/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).